Weight-Loss Drug Rivalry Entices Employers to Mull Plan Coverage

Eli Lilly & Co.'s weight loss drug Zepbound’s approval by the Food and Drug Administration introduces a cheaper option to a growing market, increasing the pressure on employers to give workers access to these in-demand medications through their health plans.

Employer plans are evaluating their options due to the high cost of the drug, even though Eli Lilly plans to sell its medication approved Nov. 8 at about $1,060 a month, 21% less than Novo Nordisk A/S’s blockbuster weight loss drug Wegovy.

“The coverage question is still a little questionable,” because of the drug’s expense, Eileen Pincay, national pharmacy practice ...